Gastrointestinal Therapeutics Market is Projected to: to Reach $52.41 Billion by 2029

 This report presents a fact-based view of the gastrointestinal therapeutics sector to help companies respond to market shifts and uncover growth potential.

 

 How Much Is The Gastrointestinal Therapeutics Market Worth?
 The gastrointestinal therapeutics market size has grown strongly in recent years. It will grow from $39.99 billion in 2024 to $42.30 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to a rise in government healthcare expenditure, an increase in early diagnosis rates, a rise in awareness programs for gut health, an increase in lifestyle-related digestive disorders, and an increase in multidisciplinary treatment approaches.
 
 The gastrointestinal therapeutics market size is expected to see strong growth in the next few years. It will grow to $52.41 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to increasing demand for biologics and targeted therapies, rising adoption of personalized medicine, rising patient preference for combination therapies, growing focus on microbiome-targeted therapeutics, and rising antibiotic-associated gastrointestinal complications. Major trends in the forecast period include technology integration in endoscopic devices, developing microbiome-based therapies, integration of digital health and remote monitoring, integration of multi-omics data in therapy development, and innovation in acid suppression therapies.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp
 
 What Are The Current Leading Growth Drivers For Gastrointestinal Therapeutics Market?
 The rising inflammatory bowel diseases is expected to propel the growth of the gastrointestinal therapeutics market going forward. Inflammatory bowel disease (IBD) is a chronic condition that causes inflammation of the digestive tract, primarily including Crohn’s disease and ulcerative colitis. The rising inflammatory bowel diseases are due to genetic susceptibility, causing an abnormal immune response to gut microbes. Gastrointestinal therapeutics help manage and treat bowel diseases by targeting underlying inflammation, regulating digestive functions, and alleviating associated symptoms to improve patient outcomes. For instance, in December 2023, according to the IBD Registry, a UK-based non-profit organization, over 5,300 individuals with inflammatory bowel diseases (IBD) were registered in 2023, marking an increase of more than 3,000 members from 2022. Therefore, the rising inflammatory bowel diseases is driving the growth of the gastrointestinal therapeutics market.
 
 Which Segment Accounted For The Largest Gastrointestinal Therapeutics Market Share?
 The gastrointestinal therapeutics market covered in this report is segmented — 
 
 1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics
 2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration
 3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications
 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
 5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users
 
 Subsegments:
 1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products
 2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics
 
 Gastrointestinal Therapeutics Market Emerging Trends And Opportunities
 Major companies operating in the gastrointestinal therapeutics market are focusing on developing innovative therapies, such as sustained-release (SR) fixed-dose combination capsules, to improve patient compliance and enhance treatment effectiveness. Sustained-release (SR) fixed-dose combination capsules are oral medications that gradually release multiple active ingredients over time to maintain consistent drug levels and reduce dosing frequency. For instance, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based pharmaceutical preparation manufacturing company, launched rabeprazole + levosulpiride SR capsules for treating gastrointestinal disorders in India. This formulation combines rabeprazole, a proton pump inhibitor that decreases stomach acid, with levosulpiride, a prokinetic agent that improves gut motility. Together, they offer effective relief from symptoms such as heartburn, acid reflux, bloating, and indigestion. This combination is widely prescribed for managing gastroesophageal reflux disease, peptic ulcers, and other related gastrointestinal (GI) conditions.
 
 Which Are The Top Companies To Hold The Market Share In Gastrointestinal Therapeutics Market?
 Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, Olympus Corporation, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation 
 
 View the full gastrointestinal therapeutics market report here:
 https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report
 
 Which Region Is Projected To Account For The Largest Share Of The Gastrointestinal Therapeutics Market?
 North America was the largest region in the gastrointestinal therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company